Logo

Cepheid Shares Up 8.4 Percent on Anthrax Detection News

Feb 16, 2006

NEW YORK, Feb. 16 (GenomeWeb News) - Shares of Cepheid were up $.80, or 8.41 percent, at $10.31 in afternoon trading after the company this morning said that its GeneXpert real-time PCR platform for mobile anthrax detection had been licensed by biothreat agencies in Oakland, Mich., and Honolulu, Hawaii.

Breaking News
The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.